Cumberland pharmaceuticals reports 38% revenue growth in q1 2025

Nashville, tenn. , may 6, 2025 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company, announced today that its product portfolio of fda-approved brands delivered combined net revenues of $11.7 million during the first quarter of 2025, a 38% increase over the prior year period.
CPIX Ratings Summary
CPIX Quant Ranking